{"version":"1.0","provider_name":"LGMD1D Foundation and Autosomal Dominant LGMD Registry","provider_url":"https:\/\/lgmd1d.org\/lgmdwp","author_name":"William Lowery MD","author_url":"https:\/\/lgmd1d.org\/lgmdwp\/author\/lgmd1d\/","title":"LGMD and GLP-1 Drugs, 2025 - LGMD1D Foundation and Autosomal Dominant LGMD Registry","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"O1D8tZv6Hv\"><a href=\"https:\/\/lgmd1d.org\/lgmdwp\/symptoms\/have-symptoms-try-symptomate\/\">LGMD and GLP-1 Drugs, 2025<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/lgmd1d.org\/lgmdwp\/symptoms\/have-symptoms-try-symptomate\/embed\/#?secret=O1D8tZv6Hv\" width=\"600\" height=\"338\" title=\"&#8220;LGMD and GLP-1 Drugs, 2025&#8221; &#8212; LGMD1D Foundation and Autosomal Dominant LGMD Registry\" data-secret=\"O1D8tZv6Hv\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/lgmd1d.org\/lgmdwp\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"Short version: There\u2019s no direct evidence that GLP-1 \/ GIP-GLP-1 drugs are inherently unsafe or absolutely contraindicated in LGMD, but there are very reasonable concerns about additional lean-muscle loss and frailty in someone who already has a primary myopathy. Any statement about \u201cGLP-1 drugs in LGMD\u201d is valid only if it\u2019s framed as \u201chigh-caution, individualized use,\u201d not \u201cnever use.\u201d \u00a0 1. What evidence actually exists in LGMD? I\u2019m not finding clinical trials or case series specifically testing GLP-1 RAs or tirzepatide in LGMD. Current LGMD drug headlines are about gene therapies or other experimental agents, not GLP-1s.Synapse+1 The recent safety scare you may have seen that mentions LGMD and a patient fatality is about an LGMD gene therapy program, not about GLP-1 drugs.Prime Therapeutics+1 So any statement about GLP-1s in LGMD is, by necessity, extrapolation, not direct data. 2. What do we know about GLP-1 \/ GIP-GLP-1 and muscle? a) Lean mass loss is real, but proportional Across large semaglutide and tirzepatide studies: Typically ~25\u201335% of the weight lost is lean mass, the rest is fat. This pattern holds for tirzepatide and high-dose semaglutide (STEP, SURMOUNT and related analyses).Wiley Online Library+1 Reviews of GLP-1 RAs and sarcopenia conclude that: They&#8230;"}